Last update Oct. 15, 2016

Cefpodoxime Proxetil

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Third-generation cephalosporin for oral administration.

Like most cephalosporins for which data are available, excretion occurs in breast milk in very small amount and it is clinically insignificant (FDA 2013).

Cephalosporins are widely used in the Pediatric practice with a good tolerance, even in the neonatal period, so it is very unlikely that in small amounts through milk would be a cause of problems in the infant.

Be aware of the possibility of false negative results of cultures in febrile infants whose mothers are taking antibiotics as well as the possibility of gastroenteritis (Ito 1993) by altering the intestinal flora.

It has been reported a case of hyperprolactinemia and galactorrhea (Khurana 2010).


We do not have alternatives for Cefpodoxime Proxetil since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Cefpodoxime Proxetil in other languages or writings:


Cefpodoxime Proxetil belongs to this group or family:


Main tradenames from several countries containing Cefpodoxime Proxetil in its composition:


Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 558 daltons
Protein Binding 22 - 40 %
VD 0.5 l/Kg
Tmax 2 - 3 hours
2 - 3 hours
M/P ratio 0.16 -
Theoretical Dose 0.055 mg/Kg/d
Relative Dose 1.6 %
Ped.Relat.Dose 0.55 %


  1. FDA. Cefpodoxime. Drug Summary. 2013 Full text (in our servers)
  2. AEMPS. Cefpodoxima. Ficha técnica. 2012 Full text (in our servers)
  3. Khurana V, Gambhir IS. Cefpodoxime-induced hyperprolactinemic galactorrhea. Ann Intern Med. 2010 Abstract
  4. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  5. Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992 Abstract
  6. Tremblay D, Dupront A, Ho C, Coussediere D, Lenfant B. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother. 1990 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM